Rein Therapeutics Inc (RNTX) FinancialsRNTXFinancialRein Therapeutics Inc

Evaluating the bottom line, Rein Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -753.55%, provide a clear picture of how effectively RNTX converts its operational activities into shareholder value.

In the context of the broader market, RNTX competes directly with industry leaders such as EDSA and TLPH. With a market capitalization of $69.53M, it holds a leading position in the sector. When comparing efficiency, RNTX's gross margin of N/A stands against EDSA's N/A and TLPH's N/A. Such benchmarking helps identify whether Rein Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Rein Therapeutics has reported consistent losses, with a net income loss of $63.75 million in Q2 2026. The company's current ratio improved to 4.27 in Q2 2026, indicating better short-term liquidity, but the overall financial health remains concerning due to ongoing losses.